Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Arkus
Nopriyati
Department of Dermatology and Venereology, Faculty of Medicine, Unibversitas Sriwijaya, Palembang, Indonesia
Religion Humanities Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
An Overview of Psoriasis Vulgaris Nopriyati; Reza Mayasari
Arkus Vol. 4 No. 1 (2018): ARKUS
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/arkus.v4i1.72

Abstract

Psoriasis is a chronic inflammatory skin disease with a genetic basis, characterized by impaired growth and differentiation of the epidermis, multiple biochemical, immunological, and vascular disorders. The aetiology of psoriasis is not known with certainty, thought to be triggered by an immune response due to environmental factors such as trauma, infection, or drugs in individuals who are genetically at risk of psoriasis. The pathogenesis of psoriasis begins with an inflammatory immune response that promotes the release of dendritic cells, T cells, keratinocytes, neutrophils, and cytokines.
Advances in Psoriasis Biological Agent Nopriyati; Reza Mayasari
Arkus Vol. 5 No. 1 (2019): ARKUS
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/arkus.v5i1.76

Abstract

Biological agents are proteins that have pharmacological activity, derived from living materials, either from humans, animals, or microorganisms, and can be synthesized in large quantities with the help of genetic engineering techniques (recombinant DNA techniques). Biological agents are divided into three types: monoclonal antibodies in humanized, primatized, fully human, chimeric; cytokines or recombinant human cytokines growth factors; and 3) fusion proteins. The nomenclature for receptor fusion proteins and monoclonal antibodies follows the rules established by the International Nonproprietary Names of the World Health Organization (WHO). The suffix "-cept" is used as a code to identify a drug as a receptor molecule, and "-mab" is used as a code for a monoclonal antibody. The origin of the antibody is indicated by the code "-u-" for fully human origin (e.g., secukinumab). Antibodies derived from humans and mice are humanized, code named "-Zu-" (e.g., ixekizumab or chimeric, "-xi-" (eg, infliximab).
Co-Authors Reza Mayasari